InvestorsHub Logo

EIT

Followers 1
Posts 380
Boards Moderated 0
Alias Born 05/09/2017

EIT

Re: RobotMaster post# 83289

Thursday, 03/07/2019 11:23:59 AM

Thursday, March 07, 2019 11:23:59 AM

Post# of 140464
Yes, it will raise PPS. Important to remember that there was no design freeze ahead of promising pre-clinical studies end of 2018, yet the stock climbed till 15$, but this was squashed with the delay.

This time, with a design freeze, is a much clearer message to the market that there not only will not be a delay, but also likely even better pre-clinical results with improvements.

The first pre-clinical studies will immediately follow design freeze. So it stands to reason that we will climb into that range 10-15 fairly quickly (by the fall) following an initial bump in PPS with design freeze (early summer). My guess is 6-8 early summer.

We'd want that to happen, to have the 40 million in warrants for Q3 and Q4, and a bit beyond. Otherwise, yet another financing (but it is becoming less and less relevant). Things are pretty bright at this point as is.

End of year, anything is possible with successful human trials and FDA submission as far as PPS. That will give us some wild press...tummies with no scars....road shows as we wait for FDA approval...and some real initial serious interest from acquirers..